Details for Patent: 8,389,542
✉ Email this page to a colleague
Title: | Dosage unit comprising a prostaglandin analog for treating constipation |
Abstract: | A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention includes a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects. In particular, the dosage unit includes a prostaglandin (PG) analog represented by Formula (I) and/or its tautomers, and a pharmaceutically suitable excipient, wherein the dosage unit contains the PG analog in an amount of 24 .mu.g+/-10%: ##STR00001## |
Inventor(s): | Ueno; Ryuji (Potomac, MD), Patchen; Myra L. (Fairfax, VA) |
Assignee: | Sucampo AG (Zug, CH) |
Filing Date: | Dec 20, 2011 |
Application Number: | 13/330,942 |
Claims: | 1. A dosage unit comprising a prostaglandin (PG) analog represented by Formula (I) and/or its tautomers, and a pharmaceutically suitable excipient, wherein the dosage unit contains said PG analog in an amount of 24 .mu.g+/-10%: ##STR00014## where A.sub.1 and A.sub.2 are fluorine atoms and B is --COOH, including its pharmaceutically acceptable salts, esters or amides. 2. The dosage unit of claim 1, wherein said PG analog is the monocyclic tautomer of formula (I). 3. The dosage unit of claim 1, wherein said PG analog is the bi-cyclic tautomer of formula (I). 4. The dosage unit of claim 1, wherein said pharmaceutically suitable excipient is orally acceptable. 5. The dosage unit of claim 1, wherein said pharmaceutically suitable excipient is a medium chain fatty acid. 6. The dosage unit of claim 1, wherein B is --COOH. 7. The dosage unit of claim 1, which is suitable for use in a human patient. 8. The dosage unit of claim 7, which is suitable for use in relieving or preventing constipation. 9. The dosage unit of claim 5, wherein B is --COOH. 10. The dosage unit of claim 1, wherein the PG analog is present in an amount of 24 .mu.g. 11. The dosage unit of claim 10, wherein B is --COOH. 12. The dosage unit of claim 10, wherein said pharmaceutically suitable excipient is a medium chain fatty acid. 13. The dosage unit of claim 11, wherein said pharmaceutically suitable excipient is a medium chain fatty acid. |